ADVFN - News

Dow Jones

42,063.36

0.09%

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Unknown symbol

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
21/09/2024	07:00	PR Newswire (US)	Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer
21/09/2024	06:00	PR Newswire (US)	Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
21/09/2024	05:30	PR Newswire (US)	Translumina Therapeutics, India's largest domestic player in the coronary stents market, announces the initiation of direct operations in the UAE
21/09/2024	05:30	PR Newswire (US)	Translumina Therapeutics, India's largest domestic player in the coronary stents market, announces the initiation of direct operations in the UAE
21/09/2024	05:15	PR Newswire (US)	Cultivating a Culture of Peace: International Day of Peace Statement by Education Cannot Wait Executive Director Yasmine Sherif
21/09/2024	04:52	PR Newswire (US)	The Best Gin in the World is Uruguayan and Distilled in Colonia del Sacramento
21/09/2024	03:28	PR Newswire (US)	BrazilFoundation's XXI New York Gala Highlighted Brazilian Philanthropy, Solidarity and Resilience with a Thrilling Performance by Ludmilla
21/09/2024	02:00	PR Newswire (US)	European Wellness Unveils Premier Medical Wellness Center in Kota Kinabalu, Sabah: A Landmark in Global Healthcare
21/09/2024	02:00	PR Newswire (US)	European Wellness Unveils Premier Medical Wellness Center in Kota Kinabalu, Sabah: A Landmark in Global Healthcare
21/09/2024	01:45	PR Newswire (US)	Greenberg Traurig Advises OPKO Health in $237.5 Million Asset Sale to Labcorp
21/09/2024	01:36	PR Newswire (US)	Niutech at the Forefront: U.S.-China Circular Economy Forum Tackles "White Pollution"
21/09/2024	01:15	PR Newswire (US)	Preclinical Research with Advanced Oncology Models and Immuno-oncology Services by Altogen Labs
21/09/2024	01:00	PR Newswire (US)	SHK Law Investigates Legal Implications of Negligence in Connection with the Airport Fire
21/09/2024	01:00	PR Newswire (US)	Curious Yellow Shield Pops Up Across The Streets of Seoul's Hongdae and Itaewon Neighbourhoods
21/09/2024	00:39	PR Newswire (US)	Global Ultrasound Institute Launches GUSI Fellowships Platform: Elevating Point-of-Care Ultrasound Education
21/09/2024	00:23	PR Newswire (US)	Germany's Wehlener Sonnenuhr Recognized as One of the 10 Greatest Vineyards in the World
21/09/2024	00:14	PR Newswire (US)	South Coast AQMD Expands Lawn & Garden Incentive Program
21/09/2024	00:09	PR Newswire (US)	Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia	NYSE:BHVN	Biohaven Ltd
21/09/2024	00:00	PR Newswire (US)	TeraBox Celebrates 2nd Anniversary of Its Massively Popular Referral Program
21/09/2024	00:00	PR Newswire (US)	TeraBox Celebrates 2nd Anniversary of Its Massively Popular Referral Program
20/09/2024	23:48	PR Newswire (US)	Revolutionizing Fertilizer with Sustainable Solutions
20/09/2024	23:44	PR Newswire (US)	Keuka College Notifies Individuals of Data Security Incident
20/09/2024	23:36	UK Regulatory	Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)	EU:SAN	Sanofi
20/09/2024	23:36	UK Regulatory	Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)	BIT:SANF	Sanofi
20/09/2024	23:36	UK Regulatory	Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)	TG:SNW	Sanofi
20/09/2024	23:36	UK Regulatory	Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant	BIT:1SAN	Sanofi
20/09/2024	23:36	UK Regulatory	Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant	EU:SAN	Sanofi
20/09/2024	23:36	UK Regulatory	Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant	BIT:SANF	Sanofi
20/09/2024	23:36	UK Regulatory	Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant	TG:SNW	Sanofi
20/09/2024	23:36	UK Regulatory	Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)	BIT:1SAN	Sanofi